Amicus Therapeutics (NASDAQ:FOLD) & Seer (NASDAQ:SEER) Head-To-Head Contrast

Amicus Therapeutics (NASDAQ:FOLD) and Seer (NASDAQ:SEER) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Profitability

This table compares Amicus Therapeutics and Seer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amicus Therapeutics	-4.27%	4.15%	1.09%
Seer	-443.96%	-26.04%	-23.10%

Volatility and Risk

Amicus Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Comparatively, Seer has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Insider & Institutional Ownership

75.2% of Seer shares are owned by institutional investors. 2.2% of Amicus Therapeutics shares are owned by insiders. Comparatively, 11.3% of Seer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Amicus Therapeutics and Seer”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amicus Therapeutics	$634.21 million	7.15	-$27.11 million	($0.08)	-180.50
Seer	$16.12 million	5.95	-$73.60 million	($1.28)	-1.33

Amicus Therapeutics has higher revenue and earnings than Seer. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and target prices for Amicus Therapeutics and Seer, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amicus Therapeutics	1	9	3	0	2.15
Seer	1	0	0	0	1.00

Amicus Therapeutics presently has a consensus target price of $15.39, indicating a potential upside of 6.57%. Given Amicus Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Amicus Therapeutics is more favorable than Seer.

Summary

Amicus Therapeutics beats Seer on 10 of the 14 factors compared between the two stocks.

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.